What is SUN GENOMICS?
Sun Genomics operates at the forefront of the personalized nutrition industry, utilizing DNA sequencing to provide tailored probiotic solutions. Its flagship product, Floré, represents a paradigm shift in how consumers manage their microbiome. By analyzing stool samples to map individual microflora, the company crafts custom probiotic formulations that are delivered directly to the user. This feedback-driven model allows for iterative health improvements, as customers can retest their microbiome to track the efficacy of their personalized regimen. The company's integration of laboratory-grade science with a direct-to-consumer delivery model establishes a defensible moat in the rapidly evolving health-tech landscape.
How much funding has SUN GENOMICS raised?
SUN GENOMICS has raised a total of $12.3M across 2 funding rounds:
Angel/Seed
$3.1M
Series A
$9.3M
Angel/Seed (2019): $3.1M, investors not publicly disclosed
Series A (2020): $9.3M led by K3 Ventures, SOSV LLC, Danone Manifesto Ventures Inc, Pangaea Ventures Ltd, Human Longevity Inc, and Nascita Ventures
Key Investors in SUN GENOMICS
Pangaea Ventures Ltd
Pangaea Ventures is a leading venture capital firm specializing in hard tech, focusing on investments in start-up companies that utilize advancements in materials, chemistry, and biology to tackle significant global challenges.
K3 Ventures
K3 Ventures is a strategic investment firm that focuses on early-stage technology companies, providing both capital and operational expertise to foster innovation across diverse sectors.
SOSV LLC
SOSV is a global venture capital firm that operates deep-tech accelerator programs, focusing on life sciences, hardware, and software to support high-growth startups.
What's next for SUN GENOMICS?
With the recent capital infusion, Sun Genomics is well-positioned to scale its manufacturing capabilities and enhance its data analytics infrastructure. The company's roadmap likely includes expanding its diagnostic capabilities and deepening its research into the long-term impacts of personalized probiotics on systemic health. As the firm matures, it will likely focus on strategic partnerships within the broader healthcare ecosystem to integrate its microbiome insights into clinical settings. By maintaining its focus on data-backed health outcomes, Sun Genomics is poised to capture a larger share of the personalized wellness market while continuing to innovate in the field of gut health diagnostics.
See full SUN GENOMICS company page
